JP2019514343A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514343A5
JP2019514343A5 JP2018542268A JP2018542268A JP2019514343A5 JP 2019514343 A5 JP2019514343 A5 JP 2019514343A5 JP 2018542268 A JP2018542268 A JP 2018542268A JP 2018542268 A JP2018542268 A JP 2018542268A JP 2019514343 A5 JP2019514343 A5 JP 2019514343A5
Authority
JP
Japan
Prior art keywords
domain
seq
polypeptide
fragment
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514343A (ja
JP7117244B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/050763 external-priority patent/WO2017137954A2/en
Publication of JP2019514343A publication Critical patent/JP2019514343A/ja
Publication of JP2019514343A5 publication Critical patent/JP2019514343A5/ja
Application granted granted Critical
Publication of JP7117244B2 publication Critical patent/JP7117244B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018542268A 2016-02-12 2017-02-10 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 Expired - Fee Related JP7117244B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294413P 2016-02-12 2016-02-12
US62/294,413 2016-02-12
PCT/IB2017/050763 WO2017137954A2 (en) 2016-02-12 2017-02-10 Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Publications (3)

Publication Number Publication Date
JP2019514343A JP2019514343A (ja) 2019-06-06
JP2019514343A5 true JP2019514343A5 (enExample) 2020-03-26
JP7117244B2 JP7117244B2 (ja) 2022-08-12

Family

ID=59563610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018542268A Expired - Fee Related JP7117244B2 (ja) 2016-02-12 2017-02-10 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法

Country Status (5)

Country Link
US (2) US11214600B2 (enExample)
EP (1) EP3416979A4 (enExample)
JP (1) JP7117244B2 (enExample)
AU (1) AU2017218768B2 (enExample)
WO (1) WO2017137954A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
CN114062665B (zh) * 2020-08-05 2023-04-28 菲鹏生物股份有限公司 示踪粒子标记目标分子及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
NZ570805A (en) * 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
EP2419129A2 (en) * 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
AU2011274367B2 (en) * 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2694534B1 (en) * 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
AU2013252888B2 (en) * 2012-04-26 2018-06-14 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
US20160235832A1 (en) * 2013-10-15 2016-08-18 The Texas A&M University System Compositions and the Use of Fibrinogen Binding Motif Presence in EFB and COA for Vaccine Against Staphylococcus Aureus and Drug Delivery
AU2015209140B2 (en) * 2014-01-24 2020-01-02 William R. Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same

Similar Documents

Publication Publication Date Title
JP6317670B2 (ja) ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
RU2770209C2 (ru) Терапевтические антитела против лиганда cd40
JP2014525933A5 (enExample)
JP6251730B2 (ja) 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
JP2016529882A5 (enExample)
AU2008294038A1 (en) Antigen-binding proteins targeting S. aureus ORF0657n
JP2018514193A5 (enExample)
AU2016334290B2 (en) Antibody to hepatitis B surface antigen and use thereof
KR102058381B1 (ko) 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
EP3288974B1 (en) Type iii secretion system targeting molecules
AU2019267050B2 (en) Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
WO2018031361A2 (en) Combination therapy
WO2020029860A1 (zh) 针对狂犬病病毒的双特异性抗体及其用途
JP2023550628A5 (enExample)
JP2021508495A5 (enExample)
WO2025242094A1 (zh) 靶向bdca2的抗体或其抗原结合片段及其应用
RU2015129655A (ru) Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела
CN116715757A (zh) 全人源抗狂犬病毒中和抗体及其用途
WO2019128119A1 (zh) 一种针对破伤风毒素的全人源单克隆中和抗体及其应用
JP6556758B2 (ja) 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法
JP2024506020A5 (enExample)
JP2019511457A5 (enExample)
EP4536704A2 (en) Igf1r antibodies
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF